Pain News and Research

Latest Pain News and Research

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

MAP Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults.

27 May 2011

Gout drug success for Novartis

Novartis AG's new gout therapy drug gives patients better pain relief and significantly cuts the risk of new attacks say two late stage studies. The studies show that more than 450 patients taking Ilaris, or ACZ885, had less pain and the risk of new attacks were reduced by up to 68 percent compared to those taking an injectable steroid to treat gouty arthritis attacks, which can last for a week or more.

26 May 2011

Invida announces launch of novel atopic dermatitis symptomatic treatment

Invida Group Private Limited reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair, which will be available to patients across Asia in second half of 2011.

26 May 2011

Music therapy enhances quality of life for patients with fibromyalgia

University of Granada researchers have proven that music therapy combined with other relax techniques based on guided imagery reduces significantly pain, depression and anxiety, and improves sleep among patients suffering from fibromyalgia.

26 May 2011

AngioDynamics launches new 90 cm NeverTouch procedure kit for varicose veins

AngioDynamics announced today the launch of the new 90 cm NeverTouch procedure kit featuring a longer TRE-Sheath introducer to gain vascular access above the ankle for the treatment of varicose veins that extend below the knee.

26 May 2011

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

ProteaBio Europe SAS, announced today that the company, in partnership with Mayoly-Spindler, has successfully completed a Phase I/IIA human clinical trial for their MS1819 recombinant Lipase.

26 May 2011

Yoga improves quality of life in patients with fibromyalgia, rheumatoid arthritis

Individuals with rheumatoid arthritis who practice yoga showed statistically significant improvements in disease activity, according to a small study presented at the EULAR 2011 Annual Congress.

26 May 2011

Impact of gaming devices on finger and wrist pain in children presented at EULAR 2011

For the first time, results on the impact of gaming devices on finger and wrist pain in children were presented today at the EULAR 2011 Annual Congress. Data comparing two schools in the USA demonstrate that young children experience high levels of pain following long term use of gaming devices and mobile phones indicating that excessive gaming may negatively impact on joint health.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Coronary artery disease is a leading cause of death in U.S. women

It's a silent killer, most women don't even know they have it. It's often thought of as a man's disease and may not receive as much attention as other illnesses, but coronary artery disease (CAD) is the leading cause of death in women in the U.S. It is so common that if you combine the number of women who die from the next five leading causes of death it would equal the number of women who die from CAD.

26 May 2011

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

25 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Brain areas responsible for motor behavior might represent therapeutic targets for bipolar disorder

A new study by motor control and psychology researchers at Indiana University suggests that postural control problems may be a core feature of bipolar disorder, not just a random symptom, and can provide insights both into areas of the brain affected by the psychiatric disorder and new potential targets for treatment.

25 May 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

New cancer study finds benefit in old therapy

Cancer patients who used a 5,000-year-old combination of gentle exercise and meditation experienced significantly higher wellbeing levels, improved cognitive functioning and less inflammation compared to a control group, new University of Sydney research has found.

24 May 2011

Nerve stimulation device approved for pain

The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.

From Medtronic 24 May 2011

Disaster-response planning raises challenges for mental health services, bioethicists say

Johns Hopkins University bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions.

24 May 2011

Asymptomatic patients do not benefit from CT angiography screening

Coronary computed tomographic angiography, which can detect plaque buildup in heart vessels, is sometimes used as a screening tool to assess the risk for a heart attack. However, the usefulness of the test on low-risk patients who do not have coronary symptoms, such as chest pain, has been unclear.

24 May 2011

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular.

24 May 2011

Pain News and Research

Latest Pain News and Research

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

Gout drug success for Novartis

Invida announces launch of novel atopic dermatitis symptomatic treatment

Music therapy enhances quality of life for patients with fibromyalgia

AngioDynamics launches new 90 cm NeverTouch procedure kit for varicose veins

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

Yoga improves quality of life in patients with fibromyalgia, rheumatoid arthritis

Impact of gaming devices on finger and wrist pain in children presented at EULAR 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Coronary artery disease is a leading cause of death in U.S. women

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Brain areas responsible for motor behavior might represent therapeutic targets for bipolar disorder

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

New cancer study finds benefit in old therapy

Nerve stimulation device approved for pain

Disaster-response planning raises challenges for mental health services, bioethicists say

Asymptomatic patients do not benefit from CT angiography screening

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Pain News and Research

Latest Pain News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in